A Partner in Health
A new chapter, a new approach. Collaborating with physicians and other healthcare professionals, focusing on R&D and maintaining clinical leadership add up to innovative medical solutions that make a difference.
Work with Us
Join Covidien, where we appreciate your talent, your experience and your passion for your work. Our culture thrives because we invest in our colleagues' growth and reward their efforts.
Visit Us
COV (NYSE)
| Price: | $50.81 |
| Change: | (0.02) |
| Volume: | 2,340,018 |
Minimum 20 minute delay
-
3/11/2010 8:34:35 AM
U.S. FDA and Health Canada Approve Use of Molybdenum 99 From Maria Reactor
Approvals Will Help Ease Critical ShortageST. LOUIS, Mar 11, 2010 (BUSINESS WIRE) -- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) and Health Canada have approved the use of the Maria Research Reactor (Maria) in Poland as a site to irradiate highly-enriched uranium targets for Molybdenum 99 (Mo 99) production. Covidien will use the Mo 99 obtained from Maria in the manufacture of its Technetium 99m (Tc 99m) generators. Patients should begin to benefit from Maria-produced Mo 99 in the United States and Canada later this month. … -
3/4/2010 7:02:00 AM
Covidien to Present at Raymond James Conference
MANSFIELD, Mass., Mar 04, 2010 (BUSINESS WIRE) -- Covidien (NYSE: COV) will present at the Raymond James 31st Annual Institutional Investors Conference in Orlando, Florida, on March 9, 2010. James C. Clemmer, President, Medical Supplies, will discuss the Company in a presentation scheduled to begin at 11:35AM ET. … -
3/3/2010 11:03:00 PM
Seven-hospital multistate system serves more than 2.5 million patients a yearBOULDER, Colo., Mar 03, 2010 (BUSINESS WIRE) -- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator of mechanical ventilation and respiratory care devices, today announced it has entered into a long-term, preferred vendor partnership with the Order of Saint Francis (OSF) Healthcare System, headquartered in Peoria, Ill. After using a mix of SPO2 technologies for more than eight years, the OSF Healthcare System recently standardized to OxiMax(TM) technology for all its pulse oximetry needs. … -
3/3/2010 8:38:00 AM
Covidien Launches Oral Transmucosal Fentanyl Citrate Product
ST. LOUIS, Mar 03, 2010 (BUSINESS WIRE) -- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that Mallinckrodt Inc., a Covidien company, has launched its Oral Transmucosal Fentanyl Citrate (CII) to distributors serving retail pharmacies across the country. The U.S. Food and Drug Administration (FDA) approved the Abbreviated New Drug Application (ANDA) for Oral Transmucosal Fentanyl Citrate (CII) on October 30, 2009. The product is expected to be available at retail pharmacies in the next few weeks. …